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Abstract 51 
Despite a wealth of activity across the globe in the area of longitudinal population cohorts, 52 
surprisingly little information is available on the natural biomedical history of a number of age-53 
related neurodegenerative diseases (ND), and the scope for intervention studies based on these 54 
cohorts is only just beginning to be explored. The Joint Programming Initiative on Neurodegenerative 55 
Disease Research (JPND) recently developed a novel funding mechanism to rapidly mobilise scientists 56 
to address these issues from a broad, international community perspective. Ten expert Working 57 
Groups, bringing together a diverse range of community members and covering a wide ND landscape 58 
(Alzheimer’s, Parkinson’s, frontotemporal degeneration, amyotrophic lateral sclerosis, Lewy-body 59 
and vascular dementia) were formed to discuss and propose potential approaches to better 60 
exploiting and coordinating cohort studies. The purpose of this work is to highlight the novel funding 61 
process along with a broad overview of the guidelines and recommendations generated by the ten 62 
groups, which include investigations into multiple methodologies such as cognition/functional 63 
assessment, biomarkers and biobanking, imaging, health and social outcomes, and pre-symptomatic 64 
ND. All of these were published in reports that are now publicly available online.  65 
 66 
Introduction 67 
Neurodegenerative diseases (ND) are debilitating conditions that affect neurons, primarily in the 68 
human brain and, in some cases, the spinal cord. Neurons are typically unable to reproduce or repair 69 
themselves, so when they become damaged or die they cannot be replaced by the body. There are 70 
currently no treatments for ND, which result in the progressive degeneration and/or death of nerve 71 
cells. This causes problems with movement (called hypo-/bradykinesia, tremor or ataxias), muscle 72 
strength (called motor neurone diseases) or mental functioning (called dementias).  Dementias are 73 
responsible for one of the greatest challenges facing the world’s health and social care systems, with 74 
Alzheimer’s disease (AD) representing approximately 60-70% of all dementia cases. 75 
 76 
The Joint Programming Initiative on Neurodegenerative Disease Research (JPND) brings together 30 77 
countries to accelerate research progress in the ND field by defragmenting and aligning national 78 
investments and research agendas. Since its first call for proposals in 2011, JPND has raised more 79 
than €100 million of new money from national budgets of participating counties and has supported 80 
more than 70 trans-national research projects from EU member (and associated) states and partner 81 
countries such as Canada, Switzerland and Australia.  82 
In 2014, JPND created a novel funding mechanism to support ten new, international expert Working 83 
Groups focused on rapidly building consensus around some of the major challenges facing the use of 84 
cohorts for ND research. The purpose of this paper is to present this funding process along with a 85 
broad overview of the guidelines and recommendations generated by the ten groups, all of which are 86 
now publicly available in their full version online. Each Working Group addressed different issues that 87 
contribute to cohorts being under-used for ND research. We hope that readers considering the use 88 
of cohort studies for ND research will be interested to find out more by going to the relevant reports 89 
and full publications. 90 
 91 
 92 
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Longitudinal cohort studies in ND research 93 
Longitudinal cohort studies, which gather data on populations over time in order to establish 94 
correlations, are widely acknowledged as important resources for multi-disciplinary ND research into 95 
the causes and progression of disease (e.g., determining risk factors). Linking and comparing such 96 
studies together would allow researchers to draw broader and statistically more powerful 97 
conclusions that could lead to a far deeper understanding of disease.  Yet significant methodological 98 
variations across cohort studies, including in data collection, measurement, and analysis, impede 99 
such linkages. In short, cohort studies are not yet able to be fully leveraged for the needs of ND 100 
research, with the potential for more to be done to promote  i) untapped research opportunities 101 
they might provide, ii) best practices in data collection/analysis, and iii) accessibility of study data.  102 
In 2013, JPND published a report1 identifying gaps and cases for new activity in areas of unmet need 103 
and outlining how to add value to existing cohort investments. The report demonstrated that despite 104 
a wealth of cohort activity across Europe, surprisingly little information is available on the natural 105 
biomedical history of ND, and the scope for intervention studies based on these cohorts is only just 106 
beginning to be explored. Given the opportunities offered by the recent evidence for convergence 107 
amongst risk factors and underlying pathologies across ND, it appears essential that steps are taken 108 
to improve and coordinate existing capabilities. Examples include the links between immune system 109 
disruption and AD, protein aggregation underlying AD, PD and prion disease, the commonality in 110 
C9orf72 hexanucleotide repeat expansions between forms of frontotemporal degeneration (FTD) and 111 
amyotrophic lateral sclerosis (ALS) and the high prevalence of vascular disease that includes risk 112 
factors and clinical expression of AD (Colonna and Wang, 2016; Goedert, 2015; Rohrer et al., 2015). 113 
 114 
A novel, flexible funding mechanism to accelerate progress 115 
Based on the recommendations from the 2013 report, JPND began developing actions to produce the 116 
methodological and technical solutions required to catalyse progress in this area, both to promote 117 
better use of existing data across studies, and to provide a more interoperable approach to future 118 
data collection. 119 
 120 
Specifically, JPND devised a new funding process called a ‘rapid action’ call to bring together key 121 
leaders in the field to discuss and propose potential solutions to the barriers holding up progress. 122 
This call, launched in April 2014, established Working Groups, made up of a diverse range of 123 
community members, to collaborate across national and disciplinary borders with the ultimate aim of 124 
producing methodologies and frameworks that could help the international scientific community 125 
optimise the use of cohort studies for ND research. This could be done either by providing a 126 
framework for exploiting and harmonizing existing or planned cohort studies and/or as a basis for 127 
developing new research proposals. 128 
                                                          
 
1 http://www.neurodegenerationresearch.eu/uploads/media/JPNDAGLCS_Final_Report_Oct_2013-
version_07_01_14.pdf 
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 129 
Working Groups were identified by JPND on a competitive basis, with each group receiving up to 130 
€50k to enable it to deliver its work within six months. Twenty-two applications were received, of 131 
which ten were recommended for funding by the review panel; the successful applications, 132 
comprising some 200 researchers, represent a diverse range of ND and methodologies, as 133 
summarized in Table 1. Indeed, members of the Working Groups go beyond the 30 JPND member 134 
countries and include experts based in several additional countries, including China, Russia, 135 
Singapore and the USA. 136 
 137 
Working Groups typically brought together 10-20 leading experts to address a specific topic area, and 138 
were asked to hold two workshops over a six-month period, communicating by tele- or video 139 
conference in the time between meetings. The incorporation of external reference groups was 140 
encouraged, to ensure both objectivity of outputs and that they would be of the most use to the 141 
wider research community. 142 
 143 
The first awards were made in August 2014, just four months after the launch of the call, with the 144 
final reports for the ten Working Groups received by June 2015, followed by their publication on the 145 
JPND website in October 2015 2. 146 
 147 
Figure 1: The diagram below illustrates the Working Group approach to delivery through 148 
workshops, other communications and a final report: 149 
 150 
                                                          
 
2 http://www.neurodegenerationresearch.eu/initiatives/jpnd-alignment-actions/longitudinal-cohorts/call-for-
working-groups/reports 
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Table 1: List of ten funded Working Groups  151 
 152 
Working Group Coordinator and sponsor country Number of 
countries 
HD-READy (High-Dimensional Research 
in Alzheimer’s Disease) 
M. Arfan Ikram, Erasmus University 
Medical Centre, Rotterdam, 
Netherlands 
Sponsor country: Netherlands 
Eight 
Harmonization and innovation of 
cognitive, behavioural and functional 
assessment in neurodegenerative 
dementias 
Alberto Costa, IRCCS Fondazione 
Santa Lucia, Rome, Italy 
Sponsor country: Italy 
Nine 
NETCALS (Network of Cohort 
Assessment in ALS) 
 
 
Leonard van den Berg, University 
Medical Centre, Utrecht, Netherlands 
Sponsor country: France 
Twelve 
21st Century Eurodem - Repurposing 
Cohorts for Dementia Studies 
 
Carol Brayne, University of 
Cambridge, UK 
Sponsor country: Sweden 
Ten 
Multi-centre cohort-studies in Lewy-
body dementia: Challenges in 
harmonizing different clinical and 
biomarker protocols 
Dag Aarsland, Stavanger University 
Hospital, Stavanger, Norway 
Sponsor country: Norway 
Nine 
Presymptomatic Neurodegeneration 
Initiative (PreNI): Developing a 
methodological framework for trials in 
presymptomatic neurodegenerative 
disease 
Jonathan Rohrer, University College 
London, UK 
Sponsor country: UK 
Six 
Harmonization of biomarker 
assessment in longitudinal cohort 
studies in Parkinson’s disease 
 
 
 
Daniela Berg, Hertie-Institute for 
Clinical Brain Research and German 
Center for Neurodegenerative 
Diseases, Tübingen, Germany 
Sponsor country: Germany 
Seven 
Dementia Outcome Measures: 
Charting New Territory 
Gail Mountain, University of Sheffield, 
UK 
Sponsor country: Denmark 
Five 
Body fluid biobanking of longitudinal 
cohorts in neurodegenerative diseases 
Charlotte Teunissen, VU University 
Medical Centre, Amsterdam, 
Netherlands 
Sponsor country: Luxembourg 
Five 
METACOHORTS: Realising the potential 
of cohort studies to determine the 
vascular contribution to 
neurodegeneration 
Joanna Wardlaw, University of 
Edinburgh, Edinburgh, UK  
Sponsor country: Canada 
Eleven 
 
 
6 
 
 
 153 
Results  154 
The ten Working Groups assembled under this funding action produced wide-ranging work across a 155 
broad spectrum of ND research. Some examples of their accomplishments are highlighted below. 156 
 157 
Realising the potential of cohort studies to determine vascular contributions to neurodegeneration 158 
It is estimated that a third of all dementias are due wholly or in part to vascular disease. Although 159 
vascular risk is modifiable, little is currently understood about the vascular contribution to 160 
neurodegeneration or how to treat it. The objective of the METACOHORTS Working Group was to 161 
elucidate how cohort studies might be better leveraged to investigate these links. 162 
 163 
Led by Joanna Wardlaw from the University of Edinburgh, METACOHORTS brought together 55 164 
international experts on brain disease and dementia to survey data from more than 90 studies, 165 
representing more than 660,000 participants. The researchers uncovered a tremendous amount of 166 
new information from existing studies that had little overlap with any previous data collections, 167 
suggesting that the value of mining such data can be very high (Dichgans et al., 2016). This Working 168 
Group subsequently secured EU Horizon 2020 funding to examine mechanisms of microvascular 169 
disease as a common cause of stroke and dementia, based on multi-centre studies. Future impact of 170 
the work is expected to include the integration of stroke and dementia prevention clinics; research in 171 
AD that better assesses vascular risk factors; and research in stroke that routinely assesses cognition 172 
as well as physical outcomes. 173 
 174 
Dementia outcome measures: charting new psychosocial territory 175 
In this Working Group, Gail Mountain of the University of Sheffield coordinated a group of experts 176 
focused on identifying the best outcome measures for the assessment of psychosocial interventions 177 
in dementia research. Starting from the premise that enabling people to live well with a dementia 178 
diagnosis is a key research objective, the group aimed both to develop recommendations regarding 179 
the use of existing outcome measures and to investigate the need for new measures.  180 
When surveying the existing measures commonly used for people with dementia and their 181 
supporters, the group identified several challenges. For example, they noted that “no single theory 182 
currently provides an adequate basis for defining wellbeing in dementia,” with much of the literature 183 
rooted in a “medical loss/deficit paradigm of dementia care”3. Moreover, they found that the 184 
majority of existing measures do not enable people with dementia to report data on their own 185 
behalf, which can be problematic in light of research showing that proxy ratings (usually from carers) 186 
often conflict with those offered by the people living with dementia themselves4. The group 187 
shortlisted 33 measures for psychosocial intervention research, 16 of which were ultimately strongly 188 
                                                          
 
3 http://www.neurodegenerationresearch.eu/wp-content/uploads/2015/10/JPND-Report-Fountain.pdf 
4 Ibid.  
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recommended to the research community. The group also made a series of recommendations for 189 
novel measures. For example, the group determined that new measures not predicated upon recall 190 
should be developed.  Further recommendations called for the establishment of measures that could 191 
be self-completed by people with early or moderate stages of dementia, and for the use of special 192 
technology and visual methods for people at more advanced stages.  193 
The outputs of this group, which resulted from four face-to-face workshops, a year of desk-based 194 
work, and a consultation with people living with dementia, aim to better facilitate the collation of 195 
data from cohorts of people with dementia who participate in psychosocial research across different 196 
countries. This paves the way for data sharing, ultimately helping to shape the remit and quality of 197 
future psychosocial research across the dementia trajectory5. 198 
High Dimensional Research in Alzheimer’s Disease (HD-READy) 199 
A cornerstone of ND research has always been the use of state-of-the-art technologies and especially 200 
imaging and genetics. Thus far, these two fields have mostly operated independently, yet many 201 
methodological considerations overlap. Both are high-throughput technologies requiring specific 202 
analytical strategies. For instance, genome-wide association studies are hypothesis-free screens of 203 
the entire genome for subtle signals involved in ND; similarly, voxel-based approaches interrogate 204 
the entire brain without assuming any pre-knowledge for regions affected in ND. In the coming years, 205 
these two fields will move closer together, opening up potentially novel avenues for research, but 206 
also bringing a new set of challenges, which the HD-READy Working Group, coordinated by Arfan 207 
Ikram of the Erasmus University Medical Centre, set out to address. 208 
 209 
The starting point revolved around the question of how to approach a voxel-based, genome-wide 210 
association study in terms of the methodological, analytical, statistical, and computational challenges 211 
to overcome and perform, for each single voxel in the brain (n=1,000,000), an entire genomic screen 212 
(n=10,000,000). Using simulation and real-world datasets, the group published a set of 213 
recommendations and developed a novel analytical strategy(Adams et al., 2016; Roshchupkin et al., 214 
2016) that can aid ND research aiming to combine imaging and genetics. The recommendations are 215 
based on four HD-READy core principles: setting (population-based versus clinical), speed, sharing 216 
and statistics. International consortia, such as CHARGE (Psaty and Sitlani, 2013) and ENIGMA 217 
(Thompson et al., 2014), are already incorporating these recommendations in their workflows with 218 
respect to imaging and genetics. Importantly, this novel methodology can also easily be applied to 219 
other hypothesis-free, omics-technologies6. 220 
 221 
Multi-centre cohort studies in dementia with Lewy bodies: Harmonizing clinical and biomarker 222 
protocols 223 
This Working Group, coordinated by Dag Aarsland of Stavanger University Hospital, focused on the 224 
                                                          
 
5 Ibid. 
6 http://www.neurodegenerationresearch.eu/wp-content/uploads/2015/10/JPND-Report-Ikram.pdf 
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use of cohort studies in research on dementia with Lewy bodies (DLB). Few longitudinal studies 225 
currently exist and very little is known about the prodromal phases of DLB -- information that is 226 
crucial for both clinical management and research. This group facilitated the creation of a new 227 
European DLB consortium, which has rapidly grown and collected retrospective data on > 1200 DLB 228 
patients. Recommendations were made on how best to combine data from different existing cohorts 229 
with different protocols and to pave the way for future cohort studies7. The consortium also serves 230 
as a trial-ready cohort and study leaders have been engaged in discussions with companies aiming to 231 
carry out trials in DLB. Finally, new funding is currently being sought for a prospective study(Biundo 232 
et al., 2016). 233 
Developing a methodological framework for trials in pre-symptomatic ND 234 
Multi-centre pre-symptomatic trials aim to characterize an ND from its earliest stages, establish 235 
disease biomarkers, and develop cohorts large enough for clinical trials.  Yet pre-symptomatic trials 236 
for ND face a range of complex design and ethical challenges. The Pre-symptomatic 237 
Neurodegeneration Initiative (PreNI) Working Group, led by Jonathan Rohrer of the University 238 
College London Dementia Research Centre, catalogued these crucial challenges and drafted a set of 239 
guidelines for improved planning of future trials.   240 
The group issued a set of 14 recommendations covering trial design, inclusion criteria, and the use of 241 
biomarkers. Since measures such as time-to-symptoms can lead to lengthy clinical trials, the group 242 
advocated for the need for shorter trials, highlighting the need for ‘proximity markers,’ i.e., markers 243 
that identify a period in proximity to symptom onset. Furthermore, the group supported the use of 244 
adaptive trial design in order to increase efficiency and allow for the testing of more drugs over a 245 
shorter period. With regard to inclusion criteria, the group recommended selecting subjects for 246 
participation as early as possible, before significant irreversible neuronal loss occurs, which would 247 
require the development of imaging and fluid biomarkers for early-phase trials. The group also 248 
suggested an approach to a range of ethical issues, such as the possibility of accidental unblinding of 249 
genetic status to trial participants or the revealing of disease status in pre-symptomatic studies of 250 
sporadic disorders. The work is expected to inform the design of future drug trials in pre-251 
symptomatic disease, and particularly to lead to the earlier consideration of ethical issues8.  252 
 253 
Discussion 254 
The trans-national Working Groups mobilised under this funding action brought together scientists 255 
from across the globe to address methodological challenges that cannot, by definition, be solved 256 
within the borders of any one country alone. The JPND mechanism allowed groups to rapidly and 257 
efficiently provide toolkits to assist scientists in their research planning, both to unlock potential in 258 
existing studies and to help support new research. Indeed there has already been some evidence of 259 
                                                          
 
7 http://www.neurodegenerationresearch.eu/wp-content/uploads/2015/10/JPND-Report-Aarsland.pdf 
8 http://www.neurodegenerationresearch.eu/wp-content/uploads/2015/10/JPND-Report-Rohrer.pdf 
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this, with the funding of a proposal linked to the PreNI Working Group under the JPND-European 260 
Commission co-funded call, as well as the success of the METACOHORTS Working Group in securing 261 
Horizon 2020 funding9. The BRIDGET project, funded in 2015 by JPND, will further expand the work 262 
done by HD-READy10. More broadly, the connections made between group members have in many 263 
cases continued beyond the funding period, resulting in a rich stream of scientific publications. 264 
 265 
In addition, there is evidence that the Working Groups have stimulated new ideas.  One example 266 
comes from the group focused on harmonization and innovation of cognitive, behavioural and 267 
functional assessment in dementia, which was led by Alberto Costa of the IRCCS Fondazione Santa 268 
Lucia and Niccolò Cusano University11. This group found that the knowledge presently available on 269 
the validity, reliability and accessibility of new tools for the evaluation of cognitive disorders was 270 
limited. The goals identified by the Working Group were to achieve a shared standard set of high 271 
sensitivity and specificity tools for the pre-symptomatic stages of AD, the measurement of change 272 
during longitudinal studies, and the assessment of functional abilities. 273 
  274 
Moreover, the systematic review of all data on the reliability of image acquisition methods for 275 
vascular disease undertaken by the METACOHORTS group provides essential underpinning for future 276 
standardisation work(De Guio et al., 2016). This Working Group also recognised that cerebral 277 
microvascular disease has local and global effects on the brain, making the burden of brain damage 278 
far greater than any individual focal neurological symptom or visible lesion on a scan. As a 279 
consequence of this observation, continuing efforts are being directed at assessing variability of 280 
vascular risk versus cerebrovascular disease burden across different cohorts, examining patterns of 281 
accumulating brain damage and mechanisms, and improving clinical trial methodologies. 282 
  283 
The Working Groups continue to collaborate and share information in various ways. Building on their 284 
previous work, the PreNI group organised a successful international conference on pre-symptomatic 285 
ND in London (convened by Lancet Neurology, 19-21 October 2016). Several other groups are also 286 
working on new projects that extend their work. One example is BioLoC-PD, a Working Group led by 287 
Daniela Berg of the Hertie-Institute for Clinical Brain Research that focused on the harmonization of 288 
biomarker assessment in longitudinal cohort studies in Parkinson’s disease (PD)12. After the group 289 
established the enormous potential for future joint data analyses, members of BioLoC-PD formed a 290 
partnership for data sharing, leading to biomarker analyses with much larger and statistically robust 291 
sample sizes, as well as to the replication of biomarker data in the prodromal phase of PD(Lawton et 292 
al., 2016; Lerche et al., 2015).  293 
 294 
                                                          
 
9 http://cordis.europa.eu/project/rcn/199717_en.html 
10 http://www.neurodegenerationresearch.eu/wp-  content/uploads/2015/10/Fact-Sheet_BRIDGET_v2.pdf 
11 http://www.neurodegenerationresearch.eu/wp-content/uploads/2015/10/JPND-Report-Costa.pdf 
12 http://www.neurodegenerationresearch.eu/wp-content/uploads/2015/10/JPND-Report-Berg.pdf 
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Despite the progress made by the Working Groups, however, several limitations were identified. For 295 
instance, Working Groups reported that the short time frame of the project was a challenge. For this 296 
reason, future actions should extend the time frame to at least nine months. One Working Group 297 
expressed concern that obtaining funding for the reanalysis of existing data was more challenging 298 
than for new data, suggesting that there could be increased recognition by funders of the value of 299 
data mining and reanalysis. Since the Working Groups were identified through an open call, a 300 
concern was raised that such a mechanism might be biased toward more established members of the 301 
community including researchers who run large cohort studies and may have determined the original 302 
conditions for access.  The authors acknowledge the importance of this point, but also maintain that 303 
potential for conflict of interest could also exist in any other group set up to examine these issues. 304 
Moreover, the policy of most funders – including JPND – is now to require researchers to make their 305 
data openly available for use by other groups. To help ensure effectiveness, funders should require 306 
custodians to operate transparent access mechanisms and have independent representation on 307 
committees responsible for deciding cohort access for research purposes. By facilitating a face-to-308 
face policy development meeting around these issues away from the individual researchers’ own 309 
laboratories, the aim of JPND was to kick-start progress towards, and lay the groundwork for, the 310 
future provision of meaningful new community standards. Finally, several Working Groups noted 311 
previous difficulty in communicating their outputs and persuading the research community to adopt 312 
the recommended measures. This paper was written partly to address this need. 313 
 314 
Conclusions 315 
Research solutions are urgently needed for ND, which are associated with a huge social and 316 
economic burden, affecting not only patients but those who care for them, and numbers of patients 317 
worldwide are set to grow exponentially in coming years. Cross-border, collaborative research will 318 
play a vital role in generating future knowledge and understanding of human health and disease, as 319 
well as in the development of safe and effective treatments. 320 
 321 
Sometimes in research, enabling steps are first required before substantive studies can accelerate 322 
the pace of research progress. In the case of the ND field it is well-recognised that there is an urgent 323 
need to understand disease onset and progression as a basis for future interventions, and in 324 
principle, longitudinal cohort studies offer an excellent approach because they provide a wealth of 325 
information available over time. Yet the use of cohort studies in ND research has not been as 326 
prevalent as expected, primarily due to very practical considerations such as lack of knowledge about 327 
which cohorts are available and suitable for what purposes, as well as more fundamental 328 
methodological challenges, such as variations in data collection and measurement.   329 
 330 
The rapid, flexible funding mechanism leveraged in this action represents a new cross-border funding 331 
tool that has the potential to help accelerate scientific research rapidly and at relatively low cost. This 332 
flexible funding approach is now being extended to other JPND priority areas, with JPND again 333 
implementing the mechanism in its 2016 call for Working Groups for harmonisation and alignment in 334 
brain imaging, which draws on experience and expands the duration of the award to nine months. 335 
 336 
The JPND Longitudinal Cohort Studies Working Groups brought together some 200 leading experts to 337 
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build consensus around key challenges inhibiting research progress. The collective outputs of the 338 
Working Groups demonstrate that the ‘rapid action’ approach described here has proved efficient 339 
and effective, resulting in the stimulation of novel ideas, the formation of new partnerships for 340 
future research or data sharing and the development of best-practice frameworks that now form the 341 
essential underpinnings for future standardisation work. 342 
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